Patent application number | Description | Published |
20110090811 | Available Bandwidth Estimation in a Packet-Switched Communication Network - A system and method for determining end-to-end available bandwidth of a path in a packet-switched communication network. A multi-rate packet chirp injector injects probe traffic packets at different probing rates, u, into the network utilizing a probe chirp. A receiver samples time separation of the probe traffic packets to generate time-separation samples, which are used to calculate relative inter-packet separation strain, ε, samples at different probing rates. An Expectation-Maximization, EM, analyzer utilizes an EM algorithm to identify useful strain ε samples and to estimate parameters of a line l | 04-21-2011 |
20110176429 | METHOD, ARRANGEMENT AND SYSTEM FOR MONITORING A DATA PATH IN A COMMUNICATION NETWORK - A probing method, arrangement, and system for estimating a condition, such as available bandwidth, of a data path in a communication network including multiple nodes are described. A probe-packet sender node transmits probe packets with a sent inter-packet separation and a time-to-live towards an intermediate node. Control message packets are generated by the intermediate node when the time-to-live expires. The probe-packet sender node receives the control message packets and calculates a received inter-packet separation. An estimate of the data path condition can be generated based on the sent inter-packet separation and the received inter-packet separation. | 07-21-2011 |
20110238756 | Method For Selection of Suitable Peers in a Peer-to-Peer (P2P) Network - The present invention relates to a method for selecting suitable peers CL | 09-29-2011 |
20110270924 | Peer to Peer Network - An access network ( | 11-03-2011 |
20110276957 | MOBILE SPECIALIZED SOFTWARE CODE UPDATED - A first host ( | 11-10-2011 |
20120128000 | Systems and Methods for Measuring Available Capacity and Tight Link Capacity of IP Paths from a Single Endpoint - According to one exemplary embodiment, a method for determining the forward and reverse available capacity or tight link capacity of an IP path from a single endpoint includes the steps of: transmitting, from a source IP endpoint node toward a destination IP endpoint node, a forward packet train including a first plurality of IP test packets over the forward IP path; and receiving, at the source IP endpoint node, a corresponding reverse packet train from the destination IP endpoint node, the reverse packet train including a second plurality of IP test packets over the reverse IP path each of which correspond to a respective one of the first plurality of IP test packets. For those IP path capacity measurements embodiments which are TWAMP-based, no changes are needed to the TWAMP control protocol, e.g., since exemplary embodiments make use of padding octets to transfer additional information which can be used for available IP path capacity and tight IP link capacity calculations. | 05-24-2012 |
20120147768 | Method and Apparatus For Reducing Power Consumption in a Telecommunication Network - A method that reduces the power consumption on network nodes by taking into account the services that need to be supported by the network and the power saving capabilities of the nodes. | 06-14-2012 |
20120290677 | Dynamic Cache Selection Method and System - Node, computer software and method for selecting a resource that is available at multiple caches connected in a communication network. The method includes receiving from a user a request for the resource; identifying one or more caches of the multiple caches that store the resource; determining a total cost associated with a path between the user and each cache of the one or more caches storing the resource, the total cost including a static cost C | 11-15-2012 |
20120304175 | NETWORK PERFORMANCE MONITOR FOR VIRTUAL MACHINES - Embodiments of the present invention relate to a method and system to monitor network performance in a computer including at least one physical server having a hardware machine attached via a hypervisor to a set of virtual machines. According to an embodiment of the present invention, the system measures network performance parameters for selected packet flows in transition between the hardware machine and the virtual machines, analyzes the measured performance parameters, and identifies a source of network degradation. | 11-29-2012 |
20130058235 | SUB-PATH E2E PROBING - The present invention relates to a method and arrangement for estimating available bandwidth of sub-path of a data path. The solution is based on the sending of probe packet trains comprising inner and outer packets from a start node to an end node using different TTL values for the outer and inner packets of these probe trains. By comparing measurements using different TTL values of the inner packets, it is also possible to determine which link are the local tight link and what available bandwidth it has. | 03-07-2013 |
20130080633 | APPARATUS AND METHOD FOR MONITORING OF CONNECTIVITY SERVICES - An apparatus ( | 03-28-2013 |
20130100847 | Method And An Apparatus For Evaluating Network Performance - The present invention relates to methods and node entities for enabling active measurement for evaluating network performance in a network comprising a logical tree structure | 04-25-2013 |
20130340012 | Media Switching Unit and Method - A user terminal, media application and method for selectively downloading media content through a communication network and selectively displaying the media content at a user terminal connected to the communication network. The method includes receiving main media content at the user terminal; determining at the user terminal level whether there are streaming resources available to maintain a predetermined quality of streaming the main media content; receiving secondary media content when the streaming resources are above a predetermined level; and displaying the main media content when the streaming resources are above the predetermined level and automatically displaying the secondary media content when the streaming resources are below the predetermined level. A switching functionality of the user terminal is configured to select which media content to be displayed as a function of the streaming resources. | 12-19-2013 |
20140016493 | Method for Queuing Data Packets and Node Therefore - A method for queuing data packets is described. Upon receipt of a data packet, e.g., at an egress buffer of a node, a position within an output queue at which to place the data packet is determined. The queue position for the data packet can be determined based on various criteria, e.g., the type of the data packet and a time associated with its subsequent transmission, and timing aspects associated with the data packets which are already stored in the queue. | 01-16-2014 |
20140071832 | NETWORK FAULT LOCALIZATION - Mechanisms for monitoring communication links in a network are disclosed. A device receives a plurality of path performance indicators over a period of time. It is determined that at least some of the path performance indicators identify a path violation in a corresponding path of a plurality of paths in the network. For each path performance indicator that identifies a path violation, a communication link value associated with each communication link in the corresponding path is updated based on a path violation value. The device identifies at least one particular communication link as a problematic communication link based on a comparison between a problematic link criterion and the communication link value associated with the at least one particular communication link. | 03-13-2014 |
20140112148 | METHOD AND AN APPARATUS FOR DETERMINING THE PRESENCE OF A RATE LIMITING MECHANISM IN A NETWORK - A method and device for determining the presence of a rate limiting mechanism arranged between a sending and a receiving data communication node in a data transfer path of a communication network is presented. The method includes determining time difference values for probe packets in a train of probe packets sent from the sending node and received in the receiving node after having traversed the data transfer path during real-time operation of the data transfer path. The method further includes determining the presence of a rate limiting mechanism in the data transfer path upon detecting that an increase in the time difference value between received probe packets in the train of probe packets exceeds a threshold criterion. Other methods and devices for determining the absence of a rate limiting mechanism and corresponding computer program products are further disclosed. | 04-24-2014 |
20150109952 | SYSTEMS AND METHODS FOR MEASURING AVAILABLE CAPACITY AND TIGHT LINK CAPACITY OF IP PATHS FROM A SINGLE ENDPOINT - According to one exemplary embodiment, a method for determining the forward and reverse available capacity or tight link capacity of an IP path from a single endpoint includes the steps of: transmitting, from a source IP endpoint node toward a destination IP endpoint node, a forward packet train including a first plurality of IP test packets over the forward IP path; and receiving, at the source IP endpoint node, a corresponding reverse packet train from the destination IP endpoint node, the reverse packet train including a second plurality of IP test packets over the reverse IP path each of which correspond to a respective one of the first plurality of IP test packets. For those IP path capacity measurements embodiments which are TWAMP-based, no changes are needed to the TWAMP control protocol, e.g., since exemplary embodiments make use of padding octets to transfer additional information which can be used for available IP path capacity and tight IP link capacity calculations. | 04-23-2015 |
20150146560 | Method and Apparatus for Estimating Available Capacity of a Data Transfer Path - A method and apparatus for estimating available capacity of a data transfer path ( | 05-28-2015 |
Patent application number | Description | Published |
20090192464 | IMPLANT AND METHOD FOR ITS MANUFACTURE - An implant for percutaneous implantation through the abdominal wall for encircling and engaging an externalised length of a body duct of a human or animal patient. The implant has an exterior ring section protruding outwardly from the abdominal wall with a free end which serves for mounting of a detachable device, and an interior section extending through the abdominal wall and inside the patient for internal fixation of the implant. The exterior ring section and interior section have a common axis. The internal circumference of at least a part of the exterior ring section above the interior section is arranged with a biocompatible, integrated ingrowth means for the exterior surface of the body duct wall. | 07-30-2009 |
20100174255 | ADAPTER, LID, AND CONNECTOR FOR OSTOMY BAGS - The invention relates to an adapter attached to a human or animal body at a stoma, a detachable lid on the adapter, and a connector for connecting an ostomy bag to the adapter. The adapter includes a protruding section extending from the stoma, and a member for mounting a detachable lid onto the end of the protruding section. The adapter and lid are arranged such that the lid can be slid onto and off the adapter in a direction relatively perpendicular to the axis of the protruding section of the adapter. The connector is arranged to connect the ostomy bag to the adapter and to slide the lid off the adapter. In this way, there is no risk of odors or waste leaking from the adapter or the ostomy bag while the bag is being connected to the adapter. | 07-08-2010 |
20110196324 | IMPLANT - A percutaneous implant serves for implantation into an animal or a human body. The implant is of the kind that has an axial interior section for fixation inside the body, an axial exterior section in communication with the interior section and extending outwards from the body with a free end. The free end of the exterior section serves for mounting of a detachable device. A distal end of the interior section opposite the exterior section is provided with an anchoring section, extending radially from the distal end of the interior section. The anchoring section includes an inner anchoring ring extending from or integral with the interior section, an outer anchoring ring, and at least one connection member configured and dimensioned for resiliently connecting the inner anchoring ring with the outer anchoring ring in a manner to provide axial resilience and anchorage to the anchoring section. | 08-11-2011 |
20120289916 | PERCUTANEOUS OSTOMY IMPLANT - A method of providing a stoma with a removable connection for a receptacle includes securing an implant onto the stoma of a patient, wherein the implant has an axial interior section for fixation inside the body and an axial exterior section extending outwards from the body, a free end of the exterior section accommodates mounting of a detachable device, and a distal portion of the interior section includes an anchoring section, extending radially from the distal portion of the interior section. The anchoring section has an inner anchoring ring, an outer anchoring ring and at least one connection member configured and dimensioned for resiliently connecting the inner and outer anchoring rings in a manner to provide axial resilience and anchorage to the anchoring section such that the anchoring section is able to respond to movements and absorb the shear of the implant in relation to adjacent organs. | 11-15-2012 |
20140249781 | MODULAR SURGICAL KIT FOR CARTILAGE REPAIR - A modular surgical kit for repair of diseased cartilage at an articulating surface of a joint and a design method for a modular surgical kit are disclosed. The modular surgical kit is adapted for removal of damage cartilage and bone and also adapted for insertion of a medical implant a grafted plug or an artificial plug having an implant body with a predetermined cross-sectional profile and adapted for guiding insert tools during repair of diseased cartilage at an articulating surface of a joint. The modular surgical kit includes an implant, and a medical implant a grafted plug or an artificial plug having an implant body with a predetermined cross-sectional profile a guide base having a positioning body with a guide hole through said positioning body and a guide body with a guide channel, the guide channel having a cross-sectional profile that is designed to correspond to the cross-sectional profile of the implant body and having a muzzle. The modular surgical kit includes a drill adjustment device being arranged to enable adjustment of the drill depth. The positioning body has a cartilage contact surface that is designed to fit the contour of cartilage or subchondral bone in the joint in a predetermined area surrounding the site of diseased cartilage. The guide hole has a muzzle on the cartilage contact surface at a position corresponding to the site of the diseased cartilage. The positioning body includes a device for releasably connecting to the guide body such that, when connected, the guide channel is positioned in relation to the positioning body such that its muzzle emanates at a site corresponding to the site of implantation into the bone. | 09-04-2014 |
Patent application number | Description | Published |
20090035375 | Pharmaceutical compositions for acute glucocorticoid therapy - The present invention relates to glucocorticoid-containing pharmaceutical compositions or kits for use in acute emergency situations where acute glucocorticoid therapy is required. Notably, the invention relates to pharmaceutical compositions and kits that are designed to be administered by non-medically trained persons outside a hospital or another medical or clinical setting. The invention also relates to a method for treating a disorder requiring acute glucocorticoid therapy by providing a fast onset of action of a glucocorticoid | 02-05-2009 |
20100062981 | USE OF FIBRINOGEN AS A PROPHYLACTIC TREATMENT TO PREVENT BLEEDING DURING AND AFTER SURGERY AND AS A BIOMARKER TO IDENTIFY PATIENT WITH AN INCREASED RISK FOR EXCESSIVE BLEEDING AND BLOOD TRANSFUSION - The present invention provides a method for preventing peri- and postoperative bleeding in subjects undergoing surgery, in particular subjects with a preoperative fibrinogen plasma level equal to or above the normal range. The method comprises administration of a substance with fibrinogen-like activity to the subject in an amount that result in a circulating fibrinogen plasma level of from about 1.0 g/L. The present invention also provides a method for determining the risk of subjects with a preoperative fibrinogen plasma level equal to or above the normal range to bleed postoperatively. Furthermore, the present invention provides means for predicting the necessity of blood or plasma transfusion after a subject with a preoperative fibrinogen plasma level equal to or above the normal range has been subject to a surgical procedure. The means involves measurement of the fibrinogen level of the subject before surgery and comparing the level with a risk curve. | 03-11-2010 |
20110020265 | USE OF OLIGOMERS OF LACTIC ACID IN THE TREATMENT OF GYNAECOLOGICAL DISORDERS - Use of the one or more oligomers of lactic acid with the following formula (I) wherein n is an integer from 2 to 25 such as, e.g., from 2 to 20, from 3 to 25, from 3 to 20, from 2 to 15, from 3 to 15, from 2 to 10, from 3 to 10, from 4 to 10, or from 4 to 9 or a lactic acid oligomeric product for the prophylaxis and/or treatment of a disease or condition that benefit of an acidic environment especially a gynaecological infection such as a bacterial infection, such as bacterial vaginosis, unspecific colpitis, senile colpitis, cervicitis, and urethritis, a fungal infection, such as candidosis ( | 01-27-2011 |
20130129823 | PHARMACEUTICAL COMPOSITIONS FOR GLUCOCORTICOID REPLACEMENT THERAPY - The invention relates to glucocorticoid replacement therapy and provides pharmaceutical compositions and kits designed to deliver one or more glucocorticoids to a subject in need thereon in a manner that results in serum levels of the glucocorticoid that essentially mimic that of a healthy subject for a clinically relevant period of time. The pharmaceutical compositions and kits are prepared in such a way that a first part of one or more glucocorticoids is substantially immediately released and a second part of one or more glucocorticoids is released over an extended period of time of at least about 8 hours. The invention also relates to a method for treating diseases requiring glucocorticoid treatment such as in subjects having a glucocorticoid deficiency disorder. | 05-23-2013 |
20140242167 | PHARMACEUTICAL COMPOSITIONS FOR GLUCOCORTICOID REPLACEMENT THERAPY - The invention relates to glucocorticoid replacement therapy and provides pharmaceutical compositions and kits designed to deliver one or more glucocorticoids to a subject in need thereon in a manner that results in serum levels of the glucocorticoid that essentially mimic that of a healthy subject for a clinically relevant period of time. The pharmaceutical compositions and kits are prepared in such a way that a first part of one or more glucocorticoids is substantially immediately released and a second part of one or more glucocorticoids is released over an extended period of time of at least about 8 hours. The invention also relates to a method for treating diseases requiring glucocorticoid treatment such as in subjects having a glucocorticoid deficiency disorder. | 08-28-2014 |
Patent application number | Description | Published |
20080206317 | Ternary Non-Lamellar Lipid Compositions - The present invention provides a particulate composition including; a) at least 50 % of at least one structure forming amphiphile, b) 0 to 40% of at least one structure swelling amphiphile, and c) 2 to 20% of at least one dispersion stabilising polymeric amphiphile, where all parts are by weight relative to the sum of the weights of a+b+c and wherein the composition comprises non-lamellar particles or forms non-lamellar particles when contacted with an aqueous fluid. Where component b) is 0% then component a) comprises at least two structure forming amphiphiles. The invention also provides pharmaceutical compositions of the compositions and kits containing the compositions for establishing a pharmaceutical formulation of an active agent. | 08-28-2008 |
20080274176 | Pharmaceutical Lipid Compositions - The present invention relates to a particulate composition containing; a) 5 to 90% of at least one phosphatidyl choline component b) 5 to 90% of at least one diacyl glycerol component, at least one tocopherol, or mixtures thereof, and c) 1 to 40% of at least one non-ionic stabilising amphiphile, where all parts are by weight relative to the sum of the weights of a+b+c and where the composition contains particles of at least one non-lamellar phase structure or forms particles of at least one non-lamellar phase structure when contacted with an aqueous fluid. The invention additionally relates to pharmaceutical formulations containing such compositions, methods for their formation and methods of treatment comprising their administration. | 11-06-2008 |
20090069221 | Somatostatin Analogue Formulations - The present invention relates to pre-formulations of a low viscosity mixture containing: a) at least one diacyl glycerol; b) at least one phosphatidyl choline; c) at least one oxygen containing organic solvent; d) at least one somatostatin analogue; wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The formulations are useful for generating depot composition for the controlled release of somatostatin analogues such as octreotide. Methods of treatment comprising the administration of such formulations are also provided, as are pre-filled administration devices and kits containing the formulations. | 03-12-2009 |
20090170782 | Gnrh Analogue Formulations - The present invention relates to compositions forming a low viscosity mixture of: a) at least one diacyl glycerol; b) at least one phosphatidyl choline; c) at least one oxygen containing organic solvent; d) at least one GnRH analogue; Wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The invention further relates to methods of treatment comprising administration of such compositions, pre-filled administration devices and kits containing the formulations. | 07-02-2009 |
20100210519 | PEPTIDE SLOW-RELEASE FORMULATIONS - A composition for the delayed delivery of a peptide active agent comprising; i) a salt of said peptide active agent comprising at least one positively charged peptide ion and at least one negatively charged counter-ion ii) a sustained-release delivery vehicle. Wherein said at least one negatively charged counter-ion is a halide ion, preferably a chloride or bromide ion. | 08-19-2010 |
20110230569 | LIPID FORMULATIONS COMPRISING A THIOLATED ANTIOXIDANT - The present invention provides a formulation comprising:
| 09-22-2011 |
20120028890 | ACID CONTAINING LIPID FORMULATIONS - The present invention relates to compositions forming a low viscosity mixture of: i) a non-polymeric slow-release matrix ii) at least one biocompatible, (preferably oxygen containing) organic solvent; iii) at least one peptide active agent; and iv) at least one lipid soluble acid. The invention further relates to methods of treatment comprising administration of such compositions, especially in treating diabetes, and to pre-filled administration devices and kits containing the formulations. | 02-02-2012 |
20120269772 | LIPID DEPOT FORMULATIONS - The present invention relates to pre-formulations comprising low viscosity, non-liquid crystalline, mixtures of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least one phospholipid; c) at least one biocompatible, oxygen containing, low viscosity organic solvent; wherein at least one bioactive agent is dissolved or dispersed in the low viscosity mixture and wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The preformulations are suitable for generating parenteral, non-parenteral and topical depot compositions for sustained release of active agents. The invention additionally relates to a method of delivery of an active agent comprising administration of a preformulation of the invention, a method of treatment comprising administration of a preformulation of the invention and the use of a preformulation of the invention in a method for the manufacture of a medicament. | 10-25-2012 |
20140162944 | CONTROLLED RELEASE PEPTIDE FORMULATIONS - The present invention relates to compositions forming a low viscosity mixture of: a) 20-80 wt. % of at least one diacyl glycerol and/or a tocopherol; b) 20-80 wt. % of at least one phosphatidyl choline (PC); c) 5-20 wt. % of at least one biocompatible, organic mono-alcoholic solvent; d) up to 20 wt. % polar solvent e) at least one peptide active agent; f) optionally at least one antioxidant; wherein the ratio of components a:b is in the range 40:60 to 54:46; wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with excess aqueous fluid. The invention further relates to methods of treatment comprising administration of such compositions, and to pre-filled administration devices and kits containing the formulations. | 06-12-2014 |
20140193347 | LIPID DEPOT FORMULATIONS - The present invention relates to pre-formulations comprising low viscosity, non-liquid crystalline, mixtures of: | 07-10-2014 |
20140329749 | ROBUST CONTROLLED-RELEASE PEPTIDE FORMULATIONS - The present invention relates to compositions forming a low viscosity mixture of: a. 25-55 wt. % of at least one diacyl glycerol and/or at least one tocopherol; b. 25-55 wt. % of at least one phospholipid component comprising phospholipids having i. polar head groups comprising more than 50% phosphatidyl ethanolamine, and ii. two acyl chains each independently having 16 to 20 carbons wherein at least one acyl chain has at least one unsaturation in the carbon chain, and there are no more than four unsaturations over two carbon chains; c. 5-25 wt. % of at least one biocompatible, oxygen containing, low viscosity organic solvent; wherein 0.1-10 wt. % of at least one peptide active agent comprising at least one somatostatin receptor agonist is dissolved or dispersed in the low viscosity mixture; and wherein the pre-formulation forms, or is capable of forming, at least one non-lamellar liquid crystalline phase structure upon contact with an aqueous fluid. The invention further relates to methods of treatment comprising administration of such compositions, and to pre-filled administration devices and kits containing the formulations. | 11-06-2014 |
20140348903 | ROBUST CONTROLLED-RELEASE FORMULATIONS - The present invention relates to compositions forming a low viscosity mixture of: a. at least one diacyl glycerol and/or at least one tocopherol; b. at least one phospholipid component comprising phospholipids having i. polar head groups comprising more than 50% phosphatidyl ethanolamine, and ii. two acyl chains each independently having 16 to 20 carbons wherein at least one acyl chain has at least one unsaturation in the carbon chain, and there are no more than four unsaturations over two carbon chains; c. at least one biocompatible, oxygen containing, low viscosity organic solvent; wherein optionally at least one bioactive agent is dissolved or dispersed in the low viscosity mixture; and wherein the pre-formulation forms, or is capable of forming, at least one non-lamellar liquid crystalline phase structure upon contact with an aqueous fluid. The invention further relates to methods of treatment comprising administration of such compositions, and to pre-filled administration devices and kits containing the formulations. | 11-27-2014 |
20150064118 | LIPID DEPOT FORMULATIONS - The present invention relates to pre-formulations comprising low viscosity, non-liquid crystalline, mixtures of: | 03-05-2015 |
20150105332 | SOMATOSTATIN RECEPTOR AGONIST FORMULATIONS - The present invention relates to compositions forming a low viscosity mixture of: a) 20-50 wt. % of at least one diacyl glycerol; b) 20-54 wt. % of at least one phosphatidyl choline (PC); c) 5-15 wt. % of at least one biocompatible, organic mono-alcoholic solvent; d) 1 to 20 wt. % polar solvent e) 5 to 150 mg/ml of at least one peptide somatostatin receptor agonist comprising pasireotide; f) optionally at least one antioxidant; wherein the ratio of components a:b is in the range 40:60 to 54:46; wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with excess aqueous fluid. The invention further relates to methods of treatment comprising administration of such compositions, and to pre-filled administration devices and kits containing the formulations. | 04-16-2015 |
Patent application number | Description | Published |
20090248873 | Name-Address Management in Communication Networks - A network infrastructure and method for name-address management in an internetwork having a hierarchical address structure with a number of address areas on different levels of the address structure. For a given resource, a distributed name-to-address resolution chain is built up through the hierarchical address structure utilizing a set of interlinked resolution key codes for bridging between address areas. During routing of a message, name-to-address resolution is performed by successively backtracking the chain through the hierarchical address structure utilizing the interlinked resolution key codes to bridge between address areas on different levels. | 10-01-2009 |
20100309817 | METHOD AND APPARATUS FOR USE IN A NETWORK - A decentralised method is disclosed of deciding a common configuration parameter in a network. The network comprises at least one node designated to perform the method. In the method, a designated node makes a local decision relating to the configuration parameter in dependence upon information relating to its local operating environment (M | 12-09-2010 |
20110282998 | Address Allocation in a Network - A method of address allocation in a network comprises determining, from negotiations between nodes, whether a first node shall assume a server role responsible for distribution and management of network addresses to clients. If this determination is made, the first node is provided with a pool of network addresses. The invention provides a method of dynamic re-allocation of address pools between servers of the network, in accordance with, for example, network requirements or traffic load. | 11-17-2011 |